IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Phone207-556-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.21 billion
Profitability
Miscellaneous
Employees8,377
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable
IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions
What is IDEXX Laboratories' stock symbol?
IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How will IDEXX Laboratories' stock buyback program work?
IDEXX Laboratories announced that its board has approved a share buyback program on Sunday, June 4th 2017, which permits the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its stock is undervalued.
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Friday, February, 1st. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.90 by $0.08. The firm earned $549.39 million during the quarter, compared to the consensus estimate of $546.04 million. IDEXX Laboratories had a negative return on equity of 1,501.97% and a net margin of 17.03%. IDEXX Laboratories's revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 earnings per share. View IDEXX Laboratories' Earnings History.
When is IDEXX Laboratories' next earnings date?
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories issued an update on its FY19 earnings guidance on Friday, February, 1st. The company provided earnings per share (EPS) guidance of $4.66-4.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.70. The company issued revenue guidance of $2.385-2.425 billion, compared to the consensus revenue estimate of $2.41 billion.IDEXX Laboratories also updated its FY 2019 guidance to $4.66-4.78 EPS.
What price target have analysts set for IDXX?
5 equities research analysts have issued 1 year price objectives for IDEXX Laboratories' stock. Their forecasts range from $235.00 to $260.00. On average, they expect IDEXX Laboratories' stock price to reach $248.00 in the next year. This suggests a possible upside of 13.1% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.
What is the consensus analysts' recommendation for IDEXX Laboratories?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.
Has IDEXX Laboratories been receiving favorable news coverage?
News coverage about IDXX stock has been trending somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IDEXX Laboratories earned a daily sentiment score of 1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days.
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Trinity Biotech (TRIB) and Celldex Therapeutics (CLDX).
What other stocks do shareholders of IDEXX Laboratories own?
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the folowing people:
- Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
- Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
- Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
- Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
- Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)
Who are IDEXX Laboratories' major shareholders?
IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.59%), Fundsmith LLP (5.08%), Geode Capital Management LLC (1.35%), Northern Trust Corp (1.22%), MERIAN GLOBAL INVESTORS UK Ltd (1.09%) and Norges Bank (0.93%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson and William T End. View Institutional Ownership Trends for IDEXX Laboratories.
Which institutional investors are selling IDEXX Laboratories stock?
IDXX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Prudential Financial Inc., Two Sigma Advisers LP, State Treasurer State of Michigan, Millennium Management LLC, Acadian Asset Management LLC, Tekla Capital Management LLC and Columbus Circle Investors. Company insiders that have sold IDEXX Laboratories company stock in the last year include Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.
Which institutional investors are buying IDEXX Laboratories stock?
IDXX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, FMR LLC, Principal Financial Group Inc., BlackRock Inc., Samlyn Capital LLC, American Century Companies Inc., Bank of Montreal Can and Geode Capital Management LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.
How do I buy shares of IDEXX Laboratories?
Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEXX Laboratories' stock price today?
One share of IDXX stock can currently be purchased for approximately $219.27.
How big of a company is IDEXX Laboratories?
IDEXX Laboratories has a market capitalization of $18.86 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.
What is IDEXX Laboratories' official website?
How can I contact IDEXX Laboratories?
IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]
MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
